Contemporary management of patients with Type 2 diabetes

Carrie McAdam-Marx, Julia A. Gaebler, Brandon K. Bellows, Diana I. Brixner

Research output: Contribution to journalComment/debatepeer-review


Type 2 diabetes is often accompanied by other comorbidities that similarly contribute to cardiovascular risk. New antidiabetics including glucagon-like peptide-1 agonists have demonstrated blood glucose control in patients with Type 2 diabetes with a low risk of hypoglycemia and a favorable impact on bodyweight. Evidence suggests that these agents may convey benefit in managing additional cardiovascular risks. In a recent pooled analysis of randomized controlled trial data, Okerson et al. identified a significant reduction in systolic blood pressure in patients treated with exenatide, particularly in patients with elevated systolic blood pressure. This study provides further evidence that glucagon-like peptide-1 agonists confer therapeutic benefit for managing Type 2 diabetes while also managing other cardiovascular risk factors.

Original languageEnglish (US)
Pages (from-to)767-770
Number of pages4
JournalExpert review of cardiovascular therapy
Issue number6
StatePublished - Jun 2010
Externally publishedYes


  • Dipeptidyl-peptidase-4 inhibitors
  • Exenatide
  • Glucagon-like peptide-1 agonists
  • Systolic blood pressure
  • Type 2 diabetes

ASJC Scopus subject areas

  • Internal Medicine
  • Cardiology and Cardiovascular Medicine


Dive into the research topics of 'Contemporary management of patients with Type 2 diabetes'. Together they form a unique fingerprint.

Cite this